Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine the efficacy, safety and tolerability of multiple doses of RN6G in subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer
NCT00473642 · Age-Related Maculopathy, Choroidal Neovascularization
NCT00759044 · Age-Related Maculopathy, Diabetic Macular Edema
NCT00051129 · Macular Degeneration, Maculopathy, Age-Related, and more
NCT01122511 · Subfoveal Choroidal Neovascularization, Age-Related Maculopathy
NCT00775411 · Choroidal Neovascularization, Age-Related Maculopathy
Scottsdale Medical Imaging
Phoenix, Arizona
Associated Retina Consultants, Ltd.
Phoenix, Arizona
Premier Research Group Limited
Phoenix, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions